BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
6/8 — Strong
SAPHNELO (anifrolumab-fnia) by AstraZeneca is type i interferon receptor antagonists [moa]. Approved for type i interferon receptor antagonist [epc]. First approved in 2021.
Drug data last refreshed 16m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAPHNELO (anifrolumab-fnia) is a monoclonal antibody that antagonizes the Type I interferon receptor, approved in 2021 for systemic lupus erythematosus (SLE). It works by blocking interferon signaling, a key driver of lupus pathology. The drug represents a novel mechanism targeting the interferon-alpha pathway in autoimmune disease.
$0.009BPart D
PeakProduct is in peak sales phase with modest Medicare spending, indicating stable commercial infrastructure and ongoing field team investment.
Mechanism of Action
Type I Interferon Receptor Antagonists
Pharmacologic Class:
Type I Interferon Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Saphnelo Use in Females of Child-bearing Potential
Started Oct 2026
26,000,000 enrolled
Systemic Lupus Erythematosus
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
Started Apr 2026
20 enrolled
Antiphospholipid Syndrome (APS)
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Started Apr 2026
245 enrolled
Systemic Lupus Erythematosus
Anifrolumab Pregnancy Study
Started Jan 2026
627 enrolled
Systemic Lupus Erythematosus
Anifrolumab Malignancy and Serious Infections Study
Started Jan 2026
3,195 enrolled
Systemic Lupus Erythematosus
Worked on SAPHNELO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.